Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962611 · ClinicalTrials.gov registry record · Phase 1
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00962611 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 57 participants.
The verdict
NCT00962611, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Interventions
- DRUG Copanlisib (Aliqopa, BAY80-6946)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2009-11-19 |
| Est. Completion | 2016-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962611
The ClinicalTrials.gov registry entry for NCT00962611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Copanlisib (Aliqopa, BAY80-6946) is the first listed.
NCT00962611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962611 about?
NCT00962611 is a clinical study titled "BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer". The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
What is the current status of trial NCT00962611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2009-11-19. Estimated completion is 2016-02-23.
What interventions are being tested in trial NCT00962611?
The interventions under investigation include: Copanlisib (Aliqopa, BAY80-6946) (DRUG).
Who is sponsoring clinical trial NCT00962611?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.